Outlook Therapeutics, Inc. (OTLK)
Nasdaq: OTLK · Biological Products, (No Diagnostic Substances) · Iselin, NJ · filing with the SEC since 2015
Who owns Outlook Therapeutics, Inc.
As filed with the SECHolders of 5% or more
4
GMS Ventures & Investments holds 16.4% of Common Stock, par value $0.01 per share, as its SCHEDULE 13D/A filed Aug 14, 2026 says.
Directors and officers
13
report now, of 32 people on the record since 2016. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 4 named at left.
Holders of 5% or moreshare of the class, as filed
GMS Ventures & Investments
SCHEDULE 13D/A · filed Aug 14, 2026 · Common Stock, par value $0.01 per share · 22.9% in Jun 1, 2026
CVI Investments, Inc.
SCHEDULE 13G · filed Aug 19, 2026 · Common Stock, $0.01 par value per share
Empery Asset Management, LP
SCHEDULE 13G · filed Oct 13, 2026 · Common Stock, $0.01 par value per share · 4.99% in Oct 21, 2025
Tang Capital Management, LLC
SCHEDULE 13G/A · filed Feb 14, 2025 · Common Stock, par value $0.01 per share
Mitchell P. Kopin
SCHEDULE 13G · filed Apr 24, 2026 · Common Stock, par value $0.01 per share · reported falling below 5%
Great Point Partners, LLC
SCHEDULE 13G/A · filed Aug 14, 2025 · Common Stock, $0.001 par value per share · reported falling below 5%, from 6.37% in May 15, 2025
Sphera Funds Management Ltd.
SCHEDULE 13G/A · filed Feb 5, 2026 · Common Stock, par value $0.01 per share · reported falling below 5%, from 7.49% in Apr 10, 2025
Tang Capital Management, LLC
SCHEDULE 13G/A · filed Aug 14, 2025 · Common Stock, par value $0.01 per share · reported falling below 5%, from 5.6% in May 15, 2025
What OTLK reports owning in othersstakes of 5% or more, and other ties
6 subsidiaries in 6 countries, from the list filed with the 10-K filed Dec 19, 2025.
Insider tradesForm 4
0sales
10purchases
0sales on a scheduled plan
0people selling
$0sold, in dollars
$7.9Mbought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window8 of 33 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Sukhtian Faisal Ghiath | director | 0 | $0 | 0 | 2 | $200,000 |
| Haddadin Yezan Munther | director | 0 | $0 | 0 | 2 | $0 |
| Jahr Robert Charles | Chief Executive Officer | 0 | $0 | 0 | 1 | $0 |
| Kenyon Lawrence A | Chief Financial Officer | 0 | $0 | 0 | 1 | $0 |
| Gms Ventures & Investments | director | 0 | $0 | 0 | 1 | $5.0M |
| Sukhtian Ghiath M. | director | 0 | $0 | 0 | 1 | $2.5M |
| Hilzinger Kurt J | director | 0 | $0 | 0 | 1 | $200,000 |
| Thurman Randy H | director | 0 | $0 | 0 | 1 | $0 |